125 results about "Metabolomic profiling" patented technology

The present invention relates to cancer markers. In particular, the present invention provides metabolites that are differentially present in prostate cancer.

The invention discloses a method for simultaneous extraction and analysis of a metabolite group and a lipid group in microtissue. The method comprises the following steps: freeze drying to-be-analyzed microtissue, accurately weighing 1 to 25 mg of the freeze-dried microtissue and adding solvents like methanol (MeOH), methyl tert butyl ether (MTBE) and water in certain proportion for extraction; allowing a solution obtained after completion of extraction to be divided into two layers, wherein an upper layer mainly contains nonpolar metabolites and lipids, and the lower layer mainly comprises polar and medium-polar metabolites; and subjecting the upper-layer solution and the lower-layer solution to mixing in proportion and freeze-drying, then carrying out redissolving and then metabonomical analysis based on liquid chromatography-mass spectrometry, subjecting the upper-layer solution to freeze-drying and then to redissolving and carrying out lipidomical analysis based on liquid chromatography-mass spectrometry. The method has the following advantages: metabolites and lipids are extracted as many as possible through one extraction of a small amount of tissue, and through metabonomical and lipidomical analysis, the amount of a tissue sample is saved, which benefits other biochemical analysis of the tissue sample.

The invention discloses a serum specificity metabolite spectrum for a patient with a lung cancer and a building method thereof, and particularly discloses a method for carrying out liquid-phase/gas-phase chromatography mass spectrometry metabonomics analysis based on the patient suffering from the lung cancer. The method comprises the following steps: collecting fasting blood samples of a healthy and normal detected person and the patient suffering from the lung cancer 7 days before and after an operation, separating by a chromatogram column after processing; extracting and aligning original data of an instrument after adopting mass spectrometry analysis; building a mathematical model to analyze the metabolites spectrum by adopting multivariable data statistical software; comparing with the difference between an average person with the metabolites spectrum of the patient with the lung cancer, so as to determine the specificity metabolite spectrum. By adopting the method disclosed by the invention, the mutation status of the metabolite of the patient with the lung cancer can be generally and comprehensively reflected, and the serum specificity metabolite spectrum can be applied to early diagnosis of the lung cancer or a beneficial technical support is supplied for prognosis.

The present invention relates to the use of endogenous reference metabolites and a method for normalization of intensity data corresponding to amounts and/or concentrations of selected target metabolites in a biological sample of a mammalian subject, wherein said intensity data are obtained by a metabolomics analysis method with one or a plurality of endogenous reference metabolites, comprising carrying out at least one in vitro metabolomics analysis method of said selected target metabolites in said biological sample, simultaneously carrying out in the same sample a quantitative analysis of one or a plurality of endogenous reference metabolites or derivatives thereof, wherein said endogenous reference metabolites are such compounds in the biological sample which are present in the subject at an essentially constant level; and wherein said endogenous reference metabolites or derivatives thereof have a molecular mass less than 1500 Da.

The invention discloses a test method for characterizing the biological effects of smoke exposure based on metabolomics. The test method adopts the metabolomics analysis method, and the biomarker groups related to the biological effects of smoke exposure are tested in different drug administration groups. The changes between groups are used to characterize the biological responses of experimental animals placed in the smoke exposure environment. The present invention is easy to operate, and evaluates the influence of mainstream smoke on endogenous metabolites in rats, and compares the similarities and differences between the effects of natural herbal added tobacco and ordinary cigarettes on endogenous metabolites, in order to evaluate the harm reduction effect of cigarettes and its associated mechanisms provide a reliable tool.

The invention discloses a metabolomics-based pancreatic cancer diagnosis marker and a screening method thereof. The diagnosis marker comprises any one or a combination of more of 31 plasma metabolic markers. The invention also provides a method for constructing a diagnosis model by using the pancreatic cancer diagnosis marker and an application in a diagnosis kit. According to the method, non-target metabolomics analysis is carried out on the plasma of a patient through a high-efficiency liquid chromatography mass spectrometry technology, the difference metabolite between the pancreatic cancerpatient and the normal people is found through an artificial intelligence data analysis technology, and the diagnosis capability of the specific differential metabolite, namely the pancreatic cancerdiagnosis marker in the diagnosis of the pancreatic cancer is further verified through target metabolomics analysis and machine learning modeling.

The invention discloses a pancreatic ductal adenocarcinoma marker and a screening method thereof, which belongs to the field of clinical test and diagnosis. In view of the problem that the detection sensitivity and the detection specificity of the existing pancreatic ductal adenocarcinoma diagnosis marker are poor, serum of an early patient of early stage pancreatic duct adenocarcinoma is subjected to a trace metabolomics analysis by the high-performance liquid chromatography-tandem mass spectrometry technology, and different metabolites between normal human and the early stage pancreatic ductal adenocarcinoma patients are found. The different metabolites between normal human and pancreatic ductal adenocarcinoma patients are further analyzed by this technique to find the specific differentmetabolites C10:1 acyl carnitine and lysophosphatidyl choline LysoPC (14:0) of pancreatic ductal adenocarcinoma patients caused by cancer, i.e., the diagnostic molecules of the pancreatic ductal adenocarcinoma. According to the pancreatic ductal adenocarcinoma marker and the screening method thereof, the method can assist CA19-9 in diagnosing pancreatic duct adenocarcinoma patients, and can improve the diagnosis rate for the CA19-9 negative patients by 85%. The method is suitable for the screening of tumor markers.

The invention discloses a metabolism group method for distinguishing false positive mass spectra peak signals and quantificationally correcting mass spectra peak area. The invention provides a metabolism group study method; by the method, the biological source and non-biological source mass spectra peak signals can be effectively distinguished; the mass spectra peak signals are quantificationally evaluated; the mass spectra peaks with poor quantification performance are excluded; through QC sample dilution, a relative content correction model is built; the mass spectra peak area is corrected. The method has the maximum characteristics that the false positive mass spectra signals can be effectively eliminated, so that the metabolism group data becomes reliable; the real biomarkers can be favorably screened. The method can aim at plant, animal and microbe samples; the method can also be suitable for the mass-spectra-platform-based metabolism group analysis of GC-MS, LC-MS and CE-MS.

The invention relates to a targeting qualitative and quantitative metabonomic technical analysis method used for screening cancer biomarkers based on the LC-MS/MS technology. The method is characterized in that a structure prediction function of multi-reaction monitoring-dependent information acquisition-enhanced daughter ion detection on correlative metabolites and a structure identification function of a high-resolution mass spectrum are predicted by fully utilizing a multi-reaction monitoring quantitation function of the high performance liquid-tandem mass spectrum, and the analysis methodsuitable for screening biomarkers of various cancers is formed. The method has the advantages of high flux, good stability and high adaptability, and improves sensitivity and accuracy of screening andfinding of metabonomic biomarkers.

The invention discloses a metabonomics analysis method base on acute anaphylactic reaction. The invention mainly starts from the systems biology, and applies a UPLC-QTof/MS technology platform for UPLC and SPE-RRLC-Q-TOF combination, and establishes an acute anaphylactic reaction guinea pig serum metabonomics evaluation model, and provides a basis for further research of medicament acute anaphylactic reaction. During analysis, the UPLC and SPE-RRLC-Q-TOF combination technology is used for detecting serum samples of normal guinea pig and experiment guinea pig with acute anaphylactic reaction generated by induction, and a metabolome spectrogram is obtained by an acquisition method after optimization, and a mode identification method suitable for evaluating animal acute anaphylactic reaction is established for analyzing the metabolome data, which establishes a base for subsequently and furtherly screening biological tag with characteristics and developing a new animal acute anaphylactic reaction detection method.

The invention relates to a construction method for a differential expression profile model of hepatitis B virus (HBV) infectivity and alcoholic cirrhosis. According to the method, peripheral blood samples of liver cirrhosis patients with HBV infections, alcoholic cirrhosis patients and healthy people are sampled to carry out nulcear magnetic resonance analysis, then a multi-variable statistical analysis is adopted for the resulting spectrograms from the nulcear magnetic resonance analysis to obtain the differential expression profile model of the HBV infectivity and the alcoholic cirrhosis. According to the present invention, the metabonomics analysis method is adopted for analyzing the metabolic products of the liver cirrhosis patients with HBV infections, the alcoholic cirrhosis patients and the healthy people, such that the specific metabolic products related to the pathologic mechanisms of the liver cirrhosis with the HBV infection and the alcoholic cirrhosis are found, the differential expression profile model of the HBV infectivity and the alcoholic cirrhosis is constructed; such that a support is provided for specific diagnosis and treatment of the liver cirrhosis with the HBV infection and the alcoholic cirrhosis. In addition, the invention further relates to a differential expression profile model of the HBV infectivity and the alcoholic cirrhosis.

The invention relates to a method for analyzing a Maca symbolic metabolite based on a liquid chromatography-mass spectrometry metabonomics. The method includes the steps: extracting the Maca metabolite by the aid of methyl alcohol, performing UHPLC-Q Exactive Orbitrap LC-MS analysis after preprocessing, processing data by the aid of a Compound Discover, leading the data in SIMCA14.0 software, analyzing the data by the aid of a principal component analysis (PCA) method, a partial least squares discriminant analysis (PLS-DA) method and an orthogonal-partial least squares discriminant analysis (OPLS-DA) method, and searching differential metabolites; inspecting effectiveness of PLS-DA model establishment by the aid of a substitution permutation inspection method. Results show that model establishment is effective. The analysis method is simple to operate, and Maca metabolites with different phenotypes are searched, so that the analysis method is used for distinguishing and identifying the Maca metabolites with different phenotypes.

The invention discloses a method for constructing a serum metabonomics analysis model. The construction method comprises the following steps: collecting a healthy serum sample and an ill serum sample; performing LC-MS detection on the samples, thereby obtaining original metabolic fingerprints; preprocessing the fingerprints, sequentially performing principal component analysis and partial least square discriminant analysis on a two-dimensional matrix, thereby obtaining a PLS-DA model; and verifying the obtained PLS-DA model, wherein if the overfitting risk does not exist, the model construction is finished. According to the method disclosed by the invention, the serum metabonomics analysis technology is applied to early screening of an esophagus cancer, the high-risk population of the esophagus cancer can be rapidly and conveniently screened by virtue of model construction, the esophagus cancer screening range is widened, the entire population screening efficiency in the high incidence area of esophagus cancer is effectively improved, the screening cost is greatly reduced, pain of partial population caused by an invasive gastroscope is effectively avoided, and the method has significant economic and social benefits and is worthy of popularization and application.

The invention relates to the technical field of analytical chemistry and biological chemistry, the traditional plasma metabonomics sample pre-process is derived for 1 hour at 70 DEG C after oximation for 2 hours at 35 DEG C, the work is heavy, time-consuming and low-efficiency. The invention provides a sample pre-processing method of plasma oximation and derivatization assisted by microwave, which comprises the steps of: adding an oximation reaction reagent to the plasma sample, carrying out the oximation reaction under the condition of low-energy and short-time microwave; adding a derivatization reagent to carry out the derivatization reaction under the condition of high-energy and medium-time microwave. The invention also applies the processing method to the analysis of plasma metabonomics with a gas chromatograph-mass spectrometer. The method in the invention is applied to the process of the plasma treatment, the processing requirement of the sample and the requirement of the metabonomics analysis are met, the pre-processing time is shortened obviously, and the analysis efficiency is improved greatly.

The invention relates to a biomarker for preoperative identification of benign and malignant thyroid nodules, a kit and application thereof. The level of 17 metabolites in peripheral blood plasma of a thyroid nodule patient is detected through metabonomics analysis, and omics analysis and a machine learning method are combined to construct a diagnosis model and evaluate the thyroid cancer diagnosis efficiency by using a subject working curve (ROC). The area of the metabolic marker combination diagnosis model composed of the metabolites under the ROC curve in thyroid nodule diagnosis can reach 95.05%, the sensitivity and specificity are both higher than 88%, and the metabolite marker combination diagnosis model can be applied to identification of thyroid benign and malignant nodules.

The invention discloses a sample pretreatment method for plant metabolome analysis. The method comprises the following steps: sampling and inactivating, sample homogenizing and grinding, centrifugal filtration and the like; various tissue parts are separately sampled, are frozen and inactivated quickly by adopting liquid nitrogen, and are homogenized and ground by high-speed oscillation in a liquid nitrogen environment; a mixed sample is extracted by adopting ultrasonic in an assistant manner after being obtained; finally, protein is removed through high-speed centrifugation. According to the sample pretreatment method, the defects of temperature change, easiness in pollution, serious sample waste, relatively poor repeatability, uneven sample mixing, relatively low work efficiency, high operating danger coefficient, high requirements on the proficiency and work experience of operating personnel and the like are overcome. The sample pretreatment method can be well applied to hard tissue sampling, homogenizing, grinding and extracting of woody plant samples of tea trees and the like, and is a rapid, nondestructive and pollution-free sample pretreatment technology for performing a metabonomics analysis test. The sample pretreatment method can also be applied to a quality component analysis, RNA (Ribonucleic Acid) extraction, a proteomics analysis and the like.

The invention relates to a method for analyzing influence of a multi-dimensional nano material on cell metabonomics. The analysis method for the influence of the multi-dimensional nano material on thecell metabonomics based on the liquid chromatography-mass spectrometry technology comprises the following steps: (1) co-culturing the multi-dimensional nano material and cells; (2) performing metabolite extraction; (3) carrying out liquid chromatography-mass spectrometry combined detection; and (4) performing bioinformatics statistical analysis. According to the metabonomics analysis method, theinteraction between the multi-dimensional nano material and cells is investigated, the cell metabolite is detected and analyzed, and the cell metabolite variety contents and the metabolic pathways under the effects of different multi-dimensional nanometer materials are compared so that the influence principle of the nanometer materials with different dimensions on the cell metabonomics is revealed, the basis is provided for the evaluation of the biological characteristics of the nanometer materials, and the application prospect is broad.

The invention discloses a urine biomarker for Japanese schistosomiasis early diagnosis. The urine biomarker is one or more of a xanthurenic acid, a naphthalenesulfonic acid, or enanthylcarnitine. Sensitivity and specificity of the marker are greater than 0.9, and an area under the curve (AUC) is greater than 0.9, indicating that the three indicators have better predictability and may be used for the Japanese schistosomiasis early diagnosis. The invention further discloses a metabolomics-based screening method for the urine biomarker for the Japanese schistosomiasis early diagnosis. By constructing a mouse Japanese schistosomiasis model, ultra performance liquid chromatography-tandem mass spectrometry is used to perform metabolomics analysis on mouse urine, and a characteristic differentialmetabolite, that is, the biomarker for the Japanese schistosomiasis early diagnosis, between a normal mouse and a Japanese schistosomiasis-infected mouse is found and analyzed. The screening method is non-invasive, convenient and fast, and can accurately reflect a metabolic spectrum difference between the Japanese schistosomiasis-infected mouse and the normal mouse and have high specificity.

The invention discloses a pancreatic cancer diagnostic marker combination as well as application and a determination method thereof. The pancreatic cancer diagnostic marker combination comprises 15 differentiated metabolites (2,5-dihydroxybenzoic acid, talopyranose, proline, glutamate, choline, 1,5-anhydro-D-glucitol, tryptophan, glutamine, betaine, 2-oxoglutaric acid, methylguanidine, adenine, glycocholic acid, valine and 2-aminobutyric acid). The invention further provides a combination of the 15 differentiated metabolites to serve as a marker for early discovery and diagnosis of pancreatic cancer, application and a diagnostic marker determination method, and the method is a liquid-phase/gas-phase chromatography-mass spectrometry combined metabonomics analysis method based on plasma/serum of patients with pancreatic cancer. The pancreatic cancer diagnostic marker combination provided by the technical scheme of the invention has the characteristics of being high in sensitiveness and specificity, has relatively high sensitiveness and specificity on early pancreatic cancer diagnosis, can be used for early discovery of pancreatic cancer, gains time for the patients to receive treatment as soon as possible, and improves the clinical treatment effect.

An ingestible capsule device collects fluid aspirates from locations within the body, locations such as the small intestine, and retains the fluid aspirates free from contamination as the capsule device is expelled from the body. The device allows for microbial and metabolomics analysis for a variety of gastrointestinal, allergic, endocrinologic, and oncologic diseases. In some examples, the capsule device is a multi-stroke device that includes a capsule shell and two reservoirs located within the shell. Check valves work in conjunction with a vacuum pressure pumping mechanism to control fluid movement from one reservoir to another, where one of the reservoirs may be expandable and permeable to some fluids. In other examples, the capsule device employs a peristaltic pump fluid control with the capsule device, and a single semi-permeable bladder stores collected fluid aspirate.